Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pfs230D1 and R21 in Matrix-M for Malaria Prevention
NCT06507605Phase 1Completed
- Sponsor
- Serum Institute of India
- Start
- Aug 2024
- Primary completion
- Jan 2026
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Pfs230D1-CRM197 in malaria, sponsored by Serum Institute of India. Primary endpoint: Immediate adverse events at 30 months. Started Aug 2024; status: completed.
02
Drugs
Pfs230D1-CRM197
03
Conditions
malaria
Beyond the preview
Go deeper on NCT06507605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06507605.